Development of malaria
vaccines that block transmission of parasites by mosquito
vectors
Hajime Hisaeda and Koji Yasutomo
|
Department of Immunology and Parasitology,
The University of Tokushima School of Medicine, Tokushima
, Japan
Abstract: Malaria is still one of the infectious diseases
urgently requiring control and causes socioeconomic burdens
on people residing in developing countries. Malaria vaccines
are expected to control the disease. However, there is no
effective vaccine available despite the intense efforts of
malaria scientists. One strategy for a malaria vaccine is
to prevent parasite spread by means of interfering with parasite
development in mosquito vectors, which is the so-called transmission-blocking
vaccine (TBV). We will here review the current progress of
TBV. J. Med. Invest. 49:118-123, 2002
Keywords:malaria vaccine, transmission-blocking vaccine, P.
falciparum, P. vivax
INTRODUCTION
Malaria is a disease caused by infection with protozoan parasite
genus Plasmodium, of which four species infect humans. It
produces up to 500 million new infections and 2 million deaths
every year (1). Chemotherapy and vector control have been
insufficient to control the disease because of the emergence
and spread of parasites and their vectors resistant to these
old chemical based control methods (2, 3). Thus, malaria vaccines
are urgently needed to control malaria especially caused by
two major species, P. falciparum and P. vivax. The malaria
parasite has a complicated life cycle (Fig. 1), which makes
difficult to develop a universal, effective and long lasting
vaccine. However, several studies suggested that vaccines
against each parasite stage are feasible as part of a control
strategy.
LIFE CYCLE OF MALARIA PARASITE AND VACCINE TARGETS
Infection is initiated by inoculation of sporozoites, an infectious
form of the parasite, through mosquito bites. Once inoculated,
sporozoites spend less than 30 minutes in the blood before
entering heptocytes or being eradicated. In heptocytes, a
single sporozoite develops into 30,000-40,000 merozoites,
each of which, when released into the bloodstream, continues
its life cycle in red blood cells. Specific antibodies to
sporozoites can inhibit entry to hepatocytes (4). During hepatic
development, a variety of liver-stage-specific antigens are
synthesized by the parasite and are presented in context with
MHC class I molecules and recognized by CD8+ T cells (5).
Vaccines against parasites before merozoite release called
liver-stage vaccine are expected to induce antibodies that
inhibit invasion of hepatocytes and cytotoxic T cells that
destroy infected liver cells. Successful vaccines can reduce
the chance of a person becoming sick because all symptoms
appear during the asexual growth stage in the blood cycle.
In the bloodstream each merozoite invades a red blood cell
and asexually divides up to 24 merozites in the host cell
over a period of 2 to 3 days. Mature parasites rupture the
host cell to infect new red blood cells, which causes the
periodic elevation of body temperature (fever). Antibodies
to merozoite can inhibit invasion of red blood cells (6).
Antibodies to parasite-derived molecules on the surface of
infected red blood cells can prevent adhesion to capillary
endothelial cells, responsible for pathogenicity of major
complications such as cerebral malaria. Vaccines against parasites
undergoing the blood cycle are called blood-stage vaccines.
Effective vaccines will reduce disease severity and the risk
of death during infection.
A part of the blood-stage parasite develops to a sexual parasite,
male and female gametocytes, instead of repeating the asexual
cycle. Gametocytes are ingested by mosquitoes during blood
sucking and they undergo the sexual process (sporogony). The
TBVs focused on here are designed to prevent parasites spread
by inhibiting development of parasites within mosquito vectors.
TRANSMISSION-BLOCKING VACCINE AND ITS EFFECT
Gametocytes ingested by susceptible species of mosquito shed
the host erythrocyte and the female develops into a macrogamete
and the male becomes eight microgametes. Gametes mate, and
the fertilized zygotes transform to motile ookinetes that
penetrate the mosquito midgut peritrophic matrix and midgut
epithelial cells. Then they develop into oocysts on the serous
membrane. Matured oocysts release sporozoites that migrate
to the salivary glands to prepare the next infection. TBVs
are designed to induce antibodies that disrupt at least one
of these steps when ingested with parasite-infected blood.
Unlike two other malaria vaccines, TBV does not provide direct
protection to individuals infected vaccine. However, this
vaccine was suggested to be one of the important strategies
for integrated malaria control program. Primarily, TBV will
reduce the incidence of malaria patients in the community
whose residence is vaccinated. In addition, this would control
the escape of parasite mutants from vaccines targeted to other
stages of the parasites life cycle (7), which would prolong
the effective life of other malaria vaccines.
TRANSMISSION-BLOCKING VACCINE CANDIDATES
Target molecules for TBV must be expressed by the sexual stage
parasites, gametocytes to ookinetes (Fig. 2). Several candidate
molecules expressed by the sexual stage parasites have been
reported. They are mostly from P. falciparum responsible for
nine of ten deaths.
1. Pfs230
Pfs230 is cloned as a molecule expressed by gametocytes of
P. falciprum and its molecular size is 230 kDa (8). The expression
remains after gametes fertilize and transform to zygotes (9).
Antibodies against Pfs230 completely block transmission of
the parasite to mosquito vectors when ingested with a gametocytemic
bloodmeal through a membrane-feeding apparatus (10).
2. Pfs48/45
Pfs48/45 is also a molecule expressed by gametocytes of P.
falciparum and shows on electric doublet of 48 and 45 kDa
on polyacrylamide gel electrophoresis (11). The expression
pattern is similar to that of Pfs230. A rodent parasite disrupted
gene encoding P48/45 homologue demonstrates that P48/45 family
is essential for male gamete fertility (12). Antibodies against
this molecule also completely block parasite transmission
to mosquitoes (13).
3. Pfg27
Pfg27 is expressed as early as gametocytogenesis (14). P.
falciparum disrupted gene encoding Pfg27 fails to develop
the sexual stage parasites, suggesting that this molecule
functions at an early stage of gametocytogenesis in vertebrate
hosts (15). This also generates antibodies that block parasite
transmission (16).
4. Chitinase
Ookinetes secrete chitinase, an enzyme that hydrolyses chitin,
a polymerized form of N-acetyl glucosamine (17). Chitin is
a major component of mosquito peritrophic matrix and its rigid
structure was suggested to function as a physical barrier
to parasite invasion. Chitinase is essential to penetrate
the peritrophic matrix because a chitinase inhibitor and disruptant
of chitinase gene suppresses oocyst formation (18, 19). Thus,
this represents a target molecule not only for the transmission-blocking
vaccine strategy but also drug development (20).
5. Pfs25/Pvs25, Pfs28/Pvs28
The leading candidates for a transmission-blocking vaccine
against P. falciparum have been cloned (21). Pfs25 and Pfs28
are expressed on the surface of ookinetes and are composed
of four tandem epidermal growth factor-like domains, putatively
anchored to the surface membrane by a glycosylphosphatidylinositol-attached
motif. Yeast-produced recombinant proteins elicit transmission-blocking
antibodies in animal models(22). Their homologs of P. vivax,
Pvs25 and Pvs28, were recently cloned (23).
DEVELOPMENT OF TBV AGAINST VIVAX MALARIA BASED ON Pvs25
Among these vaccine candidates, the most advanced is P25 and
P28 family proteins of P. falciparum and P. vivax, Pfs25,
28 and Pvs25, 28. TBV against P. vivax based on Pvs25 and
Pvs28 were recently developed. Pvs25 and Pvs28 are successfully
expressed as recombinant proteins by yeast Saccharomyces cerevisiae
and the products are highly immunogenic and induce antibodies
that block oocyst formation in mosquito when mixed with a
gametocytemic blood meal (24). Thus, both proteins are potentially
vaccine candidates. Gene knock-out experiments demonstrate
that rodent malaria parasites deficient for the P25 and P28
proteins fail to generate oocysts in mosquitoes, suggesting
a synergistic role in oocyst formation (25). This suggests
that maximum inhibition will be obtained when antibodies to
Pvs25 and Pvs28 exist. However, detailed experiments revealed
that no synergistic effect of anti-Pvs25 and -Pvs28 antiserum
on oocyst formation was observed (26). Together with low yield,
the high frequency of variants, and the unresponsiveness in
mice in MHC-dependent manner of Pvs28, a single use of Pvs25
as a vaccine was determined as the best candidate for TBV
against P. vivax. Thereafter, Pvs25 has been tested for immunogenicity
in non-human primates (27). A clinical grade Pvs25 is currently
being produced and phase I trials will soon be conducted at
the Malaria Vaccine Development Unit, NIH (Stowers, personal
communication).
ACKNOWLEDGEMENTS
The authors would like to thank Ms. Kiyoko Suzuki and Ms.
Yasuko Koto of Environmental and Toxicological Sciences Research
Group, National Institute of Radiological Sciences for kind
help in retrieval of scientific references for this review.
OBSTACLES TO BE OVERCOME
The most serious obstacles to developing a malaria vaccine
(and other vaccines) are antigenic diversity, lack of in vitro
assay system, difficulty in conducting human trials, and selection
of an adjuvant delivery system. Comparing with two other malaria
vaccines, these obstacles are easier to be overcome for the
TBV based on Pvs25. Antigenic variation is much less frequent
in P25 family proteins (23, 28). The molecules are not exposed
to host immune systems because they are expressed only after
fertilization in the mosquito. However, this results in another
problem. Immune responses to the vaccine would not be boosted
during natural infection. Therefore, formulations may need
to be developed to extend the effective life of TBV-induced
immunity.
The immune mechanism of TBV is antibody-mediated inhibition
of parasites' development in mosquitoes. This has enabled
an ex vivo assay to be established. Mosquitoes were fed with
gametocyte-infected blood through a membrane in the presence
of immune serum. Thereafter, the number of oocysts is counted.
Using this assay, the transmission-blocking activity of serum
from human volunteers will be evaluated without requiring
experimental infection of each volunteer with malaria. This
is a big advantage to design clinical trials. In terms of
the adjuvant and delivery systems, we could be optimistic,
because alum adjuvant (only adjuvant applicable for human
use) combined with Pvs25 could induce high titers of antibody
that has strong a transmission-blocking activity in rodents
and non-human primates. Moreover, DNA vaccination also induces
a high titer of antibodies (29, Kumar, personal communication).
CONCLUDING REMARKS
Although TBV does not provide direct protection to individuals,
this is an important strategy for controlling malaria. Since
TBV could prevent the spread of escape of mutants from other
vaccines, this must be a member of a multi-component malaria
vaccine. The biggest problem common to developing malaria
vaccine is the relatively low level of commercial interest.
This is because the potential market with endemic malaria
is mainly in the developing countries who do not have economic
support. However, economic support will be obtained in the
future (ex. The Bill Gates Foundation for Malaria Vaccine
Development was established).
REFERENCES
1.World Health Organization:World malaria situation in 1994.
Wkly Epidemiol Rec 72:285-292, 1997
2.Harinasuta T, Suntharasamai P, Viravan C:Chloroquine-resistant
falciparum malaria in Thailand. Lancet 2:657-660, 1965
3.Roberts DR, Ander RG:Insecticide resistance issues in vector-borne
disease control. Am J Trop Med Hyg 50:21-34, 1994
4.Nussenzweig RS, Vanderberg J, Most H, Orton C:Protective
immunity produced by the infectio of x-irradiated sporozoites
of Plasmodium berbhei. Nature 216:160-162, 1967
5.Hoffman SL, Doolan DL:Malaria vaccines-targeting infected
hepatocytes. Nat Med 6:1218-1219, 2000
6.Good MF, Kaslow DC, Miller LH:Pathways and strategies for
developing malaria blood-stage vaccine. Ann Rev Immunol 16:57-87,
1998
7.Carter R, Mendis KN, Miller HL, Molineaux L, Saul A:Malaria
transmission-blocking vaccines - how can their development
be supported? Nat Med 6:241-244, 2000
8.Williamson KC, Criscio MD, Kaslow DC:Cloning and expression
of the gene for Plasmodium falciparum transission-blocking
target antigen, Pfs230. Mol Biochem Parasitol 58:355-358,
1993
9.Read D, Lensen AH, Begarnie S, Haley S, Raza A, Carter R:Transmission-blocking
antibodies against multiple, non-variant target epitopes of
the Plasmodium falciparum gamete surface antigen pfs230 are
all complement-fixing. Parasite Immunol 16:511-519, 1994
10.Roeffen W, Geeraedts F, Eling W, Beckers P, Wizel B, Kumar
N, Lensen T, Sauerwein R:Transmission blockade of Plasmodium
falciparum malaria by anti-Pfs230-specific antibodies is isotype
dependent. Infect Immun 63:467-471, 1995
11.Kocken CH, Jansen J, Kaan Am, Beckers PJ, Ponnudurai T,
Kaslow DC, Konings RN, Schoenmakers JG:Cloning and expression
of the gene coding for the transmission blocking target antigen
Pfs48/45 of Plasmodium falciparum. Mol Biochem Parasitol 61:59-68,
1993
12.van Dijk MR, Janse CJ, Thompson J, Waters AP, Braks JA,
Dodemont HJ, Stunnenberg HG, van Gemert GJ, Sauerwein RW,
Eling W:A central role for P48/45 in malaria parasite male
gamete fertility. Cell 104:153-164, 2001
13.Roeffen W, Lensen T, Mulder B, Teelen K, Sauerwein R, van
Druten J, Eling W, Meuwissen JH, Beckers PJ:A comparison of
transmission-blocking activity with reactivity in a Plasmodium
falciparum 48/45-kD molecule-specific competition enzyme-linked
immunosorbent assay. A J Trop Med Hyg 52:60-65, 1995
14.Alano P, Premawansa W, Bruce MC, Carter R:A stage specific
gene expressed at the onset of gametocytogenesis in Plasmodium
falciparum. Mol Biochem Parasitol 46:81-88, 1991
15.Lobo CA, Fujioka H, Aikawa M, Kumar N:Disruption of the
Pfg27 locus by homologous recombination leads to loss of the
sexual phenotype in P. falciparum. Mol Cell 3:793-798, 1999
16.Ploton IN, Wizel B, Viscidi R, Kumar N:Mapping of two overlapping
linear epitopes in Pfg27 recognized by Plasmodium falciparum
transmission-blocking monoclonal antibodies. Vaccine 13:1161-1169,
1995
17.Huber M, Cabib E, Miller LH:Malaria parasite chitinase
and penetration of the mosquito peritrophic membrane. Proc
Natl Acd Sci USA 88:2807-2810, 1991
18.Shahabudding M, Toyoshima T, Aikawa M, Kaslow DC:Transmission-blocking
activity of a chitinase inhibitor and activation of malarial
parasite chitinase by mosquito protease. Proc Natl Acd Sci
USA 90:4266-4270, 1993
19.Tsai YL, Hayward RE, Langer RC, Fidock DA, Vinetz JM:Disruption
of Plasmodium falciparum chitinase markedly impairs parasite
invasion of mosquito midgut. Infect Immun 69:4048-4054, 2001
20.Langr RC, Vinetz JM:Plasmodium ookineter-secreted chitinase
and parasite penetration of th mosquito peritrophic matrix.
Trends Parasitol 17:269-272, 2001
21.Kaslow DC Quankyi IA, Syin C, Raum MB, Keister DB, Coligan
JE, McCutchan TF, Miller LH:A vaccine candidate from the sexual
stage of human malaria that contains EGF-like domains. Nature
333:74-46, 1988
22.Kaslow DC, Bathurst IC, Lensen T, Ponnuduraoi T, Barr PJ,
Keister DB:Saccharomyces cerevisiae recombinant Pfs25 adsorbed
to alum elicits antibodies that block transmission of Plasmodium
falciparum. Infect Immun 62:5576-5580, 1994
23.Tsuboi T Kaslow DC, Gozar MMG, Tachibana M, Cao Y-M, Torii
M:Sequence polymorphism in two novel Plasmodium vivax ookinete
surface proteins, Pvs25 and Pvs28, that are malaria transmission-blocking
vaccine candidates. Mol Med 4:772-778, 1998
24.Hisaeda H, Stowers AW, Tsuboi T, Collins WE, Sattabongkot
JS, Suwanabun N, Torii M, Kaslow DC:Antibodies to malaria
vaccine candidates Pvs25 and Pvs28 completely block the ability
of Plasmodium vivax to infect mosquitoes. Infect Immun 68:6618-6623,
2000
25.Sinden-Kiamos I, Vlachou D, Margos G, Beetsma A, Waters
AP, Sinden R, Louis C:Distinct roles fo Pbs21 and Pbs25 in
the in vitro ookinete to oocyst transformation of Plasmodium
berghei. J Cell Sci 113:3419-3426, 2000
26.Hisaeda H, Collins WE, Saul A, Stower AW:Antibodies to
Plasmodium vivax transmission-blocking vaccine candidate antigens
Pvs25 and Pvs28 dono show synergism. Vaccine 20:763-770, 2001
27.Arevalo-Herrera M, Herrera S:Plasmodium vivax malaria vaccine
development. Mol Immunol 38:443-455, 2001
28.Kaslow DC, Quankyi IA, Keister DB:Minimal variation in
a vaccine candidate from the sexual stage of Plasmodium falciparum.
Mol Biochem Parasitol 32:101-103, 1989
29.Lobo CA, Khar R, Kumar N:Immunization of mice with DNA-based
Pfs25 elicits potent malaria transmission-blocking antibodies.
Infect Immun 67:1688-1693, 1999
Received for publication June 21, 2002;accepted July 4, 2002.
Address correspondence and reprint requests to Koji Yasutomo,
M.D., Ph.D., Department of Immunology & Parasitology,
The University of Tokushima School of Medicine, Kuramoto-cho,
Tokushima 770-8503, Japan and Fax:+81-88-633-7114.
|
| |